MENU

Can Eli Lilly (LLY) Stock Reach $1,580?

a manufacturer of pharmaceutical products

A.I.Advisor
published price charts
A.I.Advisor
Nov 08, 2026

Can Eli Lilly (LLY) Stock Reach $1,580?

Eli Lilly and Company (LLY), the Indianapolis-based drugmaker behind the blockbuster diabetes and obesity medicines Mounjaro and Zepbound, has been one of the strongest large-cap performers in the market, with a market value around $1.27 trillion. After a strong third-quarter report and a run to a fresh all-time high, the central question for investors is whether the shares can keep climbing toward a $1,580 price target.

Key Takeaways

  • The $1,580 central target is the arithmetic mean of 17 recently updated, individually attributed analyst price targets, most issued after late-October 2026 earnings.
  • With the stock near $1,354, reaching $1,580 would require a rise of roughly 17%, a substantial move from current levels.
  • Among the reviewed targets, the range runs from $1,400 to $1,650; the broader sell-side range extends from a bearish $940 (HSBC, Sell) to about $1,690.
  • Support comes from surging GLP-1 demand, raised full-year revenue guidance, and a deep late-stage pipeline, including retatrutide and the oral therapy Foundayo.
  • Key risks are a premium valuation, growing competition in obesity care, pricing pressure, and concentration of growth in two franchises.
  • For more detail on this name, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • Investors looking for AI-driven market insight can also explore Trending AI Robots.

Analyst Price Targets and Consensus View

The $1,580 central target reflects a review of 17 current analyst price targets attributable to specific firms, most refreshed around the company's third-quarter results. Targets cluster tightly between roughly $1,400 and $1,650, with BMO Capital, Citi, and JPMorgan near $1,650 and Berenberg at $1,400 after its upgrade to Buy. The calculated average of these 17 figures is about $1,581, rounded to $1,580.

The wider analyst universe is more dispersed. Independent aggregators report a consensus rating of Buy to Strong Buy across roughly 30-plus analysts, with a mean near $1,450 and a range spanning from HSBC's $940 Sell target to highs around $1,690. The gap reflects genuine disagreement about how much of Lilly's long-term growth is already reflected in the share price.

Recent revisions have been decidedly upward. Following the Q3 report, Cantor Fitzgerald and RBC Capital moved to $1,600, Truist to $1,612, Jefferies to $1,610, UBS to $1,625, and Scotiabank to $1,605, while Morgan Stanley and Goldman Sachs lifted targets to $1,596 and $1,573, respectively. The dominant rationale is continued GLP-1 momentum and confidence that Lilly can hold its obesity and diabetes leadership.

Current Market Position and Path Toward the Target

The stock closed near $1,354, leaving roughly 17% upside to the $1,580 target, a substantial move for a company of this size. Lilly's third-quarter results reinforced the growth narrative: revenue rose about 39% to $24.4 billion, with Mounjaro sales up roughly 65% and Zepbound up about 49%, while adjusted earnings of $7.48 per share (EPS) topped the roughly $5.38 consensus estimate. Management raised full-year revenue guidance to $91 billion–$92 billion.

The path to $1,580 would most plausibly run through sustained franchise growth, successful launches of Foundayo and retatrutide, and pipeline execution across oncology and neuroscience. The stock trades at roughly 44 times trailing earnings, a rich multiple that means upside depends on earnings catching up to valuation rather than further multiple expansion alone.

What Could Support a Move Toward the Target

Demand for Mounjaro and Zepbound remains the core engine, and analysts point to the Medicare Bridge program as a driver of broader obesity-drug access. The expected diabetes approval of Foundayo, an oral GLP-1, and late-stage data on retatrutide offer additional catalysts. Lilly has also been active in business development, completing multiple acquisitions to broaden its pipeline, and its raised full-year guidance signals management confidence in near-term growth.

What Could Prevent the Target From Being Reached

The most visible obstacle is valuation. At a premium to the broader market, the stock has little room for error if growth slows or expectations reset. Competition from Novo Nordisk and a growing field of GLP-1 challengers, alongside political and pricing pressure on obesity medicines, could compress both sales and the multiple. Because so much of Lilly's value rests on two franchises, any supply, safety, or competitive setback there would weigh disproportionately on the shares.

Technical Levels and Market Structure

Lilly recently set an all-time high near $1,453 before pulling back, making that level the key resistance to clear on any move toward $1,580. The shares found support around $1,330 in early November, with the psychological $1,300 area and the late-October breakout zone below that acting as secondary floors. The stock remains in a long-term uptrend well above its 52-week low near $850.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors should watch quarterly GLP-1 sales trends, the Foundayo approval and launch trajectory, retatrutide data, full-year guidance updates, and any shifts in Medicare coverage or drug-pricing policy. Analyst revisions and competitive data from rival obesity programs are also worth tracking.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than scanning charts manually. For investors following large-cap healthcare names, the tool offers a way to complement fundamental research with automated, data-driven signal generation.

Final Assessment

The $1,580 target, derived from the average of 17 recent analyst price targets, implies roughly 17% upside from a share price near $1,354. The bull case rests on GLP-1 demand, a raised outlook, and a promising pipeline, while the bear case centers on a rich valuation, intensifying competition, and franchise concentration. With the sell-side range stretching from $940 to roughly $1,690, expectations are unusually wide, underscoring that the path to $1,580 is far from assured. Investors should focus on franchise sales, pipeline milestones, and pricing policy rather than any single target.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

LLY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
-0.30%
JNJ - LLY
47%
Loosely correlated
+1.25%
PFE - LLY
45%
Loosely correlated
-0.51%
MRK - LLY
44%
Loosely correlated
+0.69%
NVS - LLY
43%
Loosely correlated
-0.50%
BMY - LLY
43%
Loosely correlated
+0.79%
More